TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01326468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: All patients will receive temsirolimus. The dose of temsirolimus in this study will range from 15-25 mg depending on the dose level. Temsirolimus will be infused over a 30-60 minute period once a week for the duration of radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: All patients will receive temsirolimus. The dose of temsirolimus in this study will range from 15-25 mg depending on the dose level. Temsirolimus will be infused over a 30-60 minute period once a week for the duration of radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: All patients will receive cetuximab. An initial loading dose of cetuximab 400 mg/m2, intravenously over 120 minutes at least 4 days before radiation therapy but no more than 7 days before the start of radiation therapy.~Thereafter, cetuximab will be infused at 250 mg/m2 dose over 60 minutes weekly for the duration of radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: All patients will receive cetuximab. An initial loading dose of cetuximab 400 mg/m2, intravenously over 120 minutes at least 4 days before radiation therapy but no more than 7 days before the start of radiation therapy.~Thereafter, cetuximab will be infused at 250 mg/m2 dose over 60 minutes weekly for the duration of radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: All patients in Cohort A will receive cisplatin. The dose will be 20 mg/m2 or 30 mg/m2 depending upon the dose level.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients will be treated on a linear accelerator fitted with multi-leaf collimators with 1.6-2.3 Gy fractions delivered daily 5 days per week over 4-7 weeks to a cumulative dose of 66 Gy. A variance of +/- 10% in this nominal prescription dose is allowable and will depend on the extent of residual disease, at the discretion of the attending radiation oncologist.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients will be treated on a linear accelerator fitted with multi-leaf collimators with 1.6-2.3 Gy fractions delivered daily 5 days per week over 4-7 weeks to a cumulative dose of 66 Gy. A variance of +/- 10% in this nominal prescription dose is allowable and will depend on the extent of residual disease, at the discretion of the attending radiation oncologist.
Study: NCT04170348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daily oral vitamin D3, 3,333 IU
Description: Oral vitamin D3, 3,333 IU, will be administered daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bolus oral vitamin D3, 100,000 IU
Description: Bolus oral vitamin D3, 100,000 IU, will be administered monthly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral tablet
Description: Participants randomized to receive once monthly oral bolus of vitamin D3, will receive placebo on all other days of the month.
Study: NCT04112602

Intervention type: OTHER
Intervention: Sputum
Description: Sputum will be collected after a respiratory physiotherapy session, scheduled as part of routine care.

Intervention type: OTHER
Intervention: Tracheal aspiration
Description: Tracheal aspirations will be collected in intubated patients (intubation for surgery under general anesthesia).

Intervention type: OTHER
Intervention: Tracheal aspiration
Description: Tracheal aspirations will be collected in intubated patients (intubation for surgery under general anesthesia).
Study: NCT00623935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine (40 mg/m2/day x 4 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine (40 mg/m2/day x 4 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan (3.2 mg/m2/day x 2 days or x 4 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan (3.2 mg/m2/day x 2 days or x 4 days).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Patients who receive Busulfan 3.2 mg/m2/day x 2 days and a mismatched allograft (7/8 HLA match) will also receive 200 cGy of total body irradiation (TBI) pre-transplant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Allogeneic stem cell transplant from related or unrelated donor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Allogeneic stem cell transplant from related or unrelated donor
Study: NCT03178240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: photoaging mirroring intervention
Description: selfies of the students are photoaged showing them the consequences of their UV protection behavior on their own face
Study: NCT02828124

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986183
Description: specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986183
Description: specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986183
Description: specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986183
Description: specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose on specified days
Study: NCT02770404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafithromycin
Description: 100, 200, or 400 mg of nafithromycin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV matching placebo
Study: NCT03932175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Behaviorial intervention on non-invasive ventilation use and adherence alongside lifestyle changes recommendations supported by an mHealth tool (MyPathway app)
Study: NCT03790228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Combined With Pemetrexed And Carboplatin
Description: Anlotinib(12mg, QD, PO, d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2, IV, d15-21,21 days per cycle) and Carboplatin(AUC5,IV, d15-21,21 days per cycle,using 4 cycles)
Study: NCT00286780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-101
Description: 80 mg of AT-101 once daily for three days every other week, 375 mg/m2 of rituximab weekly for up to 12 weeks
Study: NCT03788434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VE303
Description: VE303 is a live biotherapeutic product containing 8 clonal human commensal bacterial strains manufactured under Good Manufacturing Practices (GMP) conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VE303
Description: VE303 is a live biotherapeutic product containing 8 clonal human commensal bacterial strains manufactured under Good Manufacturing Practices (GMP) conditions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules contained microcrystalline cellulose and were visually identical to VE303 capsules. Placebo capsules did not contain any VE303 Drug Product.
Study: NCT05043597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Description: Thrombus aspiration
Study: NCT01151202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG NPP709syrup

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG NPP709syrup
Study: NCT02847494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide
Description: metoclopramide 10mg intravenous infusion over 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide
Description: metoclopramide 10mg intravenous infusion over 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone 10mg intramuscular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone acetate
Description: methylprednislone acetate 160mg intramuscular injection
Study: NCT01706419

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified rice cold extruded kernel

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortified rice warm extruded kernel

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortiified rice hot extruded kernel
Study: NCT03326947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, cisplatin and 5-fluorouracil
Description: Drug: TPF induction chemotherapy TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.~Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy, for high risk factors, concurrent chemotherapy with cisplatin of 80mg/m2.~Other Names:~TPF protocol group Procedure/Surgery: surgery In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.~Radiation: radiotherapy
Study: NCT04187820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. In the acupuncture group, Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustIon.
Study: NCT00114634

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg yolk preparation with cholesterol
Description: Egg yolk preparation with cholesterol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Egg substitute, without cholesterol
Description: Placebo control. Egg substitute, without cholesterol
Study: NCT00877903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochymal®
Description: Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of excipients of Prochymal®
Study: NCT03283696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Administered per standard of care
Study: NCT03788005

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early mobilization
Description: Early mobilization as soon as possible and within a maximum of 12 hours following burr hole craniostomy for chronic subdural hematomas.
Study: NCT04530357

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QazCovid-in® - COVID-19 inactivated vaccine
Description: QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QazCovid-in® - COVID-19 inactivated vaccine
Description: QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QazCovid-in® - COVID-19 inactivated vaccine
Description: QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QazCovid-in® - COVID-19 inactivated vaccine
Description: QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QazCovid-in® - COVID-19 inactivated vaccine
Description: QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
Study: NCT01544309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.~(When not reach the LDL-C level of target in the Japan Atherosclerosis Society \[JAS\] Guidelines \[GL\] after 3 months, had the atorvastatin \[ATV\] dose of 20 mg.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.~(When not reach the LDL-C level of target in JAS GL after 3 months, had the rosuvastatin \[RSV\] dose of 10 mg.)
Study: NCT04691336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational and Training with counselling
Description: The nurse conducts a structured interview that covers the following areas: information on respiratory attraction and the symptom of dyspnea, expectations and beliefs about oxygen therapy, use of oxygen therapy, healthy habits, social support. It also evaluates the patient's perception of oxygen therapy, and the level of dyspnea using the mMRC scale. After this, the nurse evaluates the current level of adherence, and if she considers that the patient needs a reinforcement session, she schedules a workshop with 3 other patients and their main caregivers. This workshop takes place 30 days after this interview. In other patients, depending on the level of adherence, a support call is made, and all patients are visited again at the center at 90 days, performing the same evaluation with a structured interview and the scales that were made on day 1
Study: NCT02971995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET Scan ou TEP-TDM
Description: Performance of the PET/CT using Flurocholine in order to detect the localization of the pathological fixation of the tracer and to determine the place where to take the biopsy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mpMRI
Description: Performance of the mpMRI in order to determine the place where to take the biopsy
Study: NCT01940692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.5g intravenous Exacyl
Description: intravenous administration of 1.5g Exacyl preoperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.0g intra-articular Exacyl
Description: 3g Intra-articular Exacyl administration postoperatively
Study: NCT04159051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regional Hyperthermia
Description: Regional hyperthermia 1-2×/week to a total number of 7-10 treatments combined with salvage radiotherapy to a total dose of 70 Gy over 7 weeks
Study: NCT03090893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATryn continuous infusion
Description: replenish serum thrombin levels
Study: NCT04530357

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%) The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (22 volunteers)
Study: NCT01215357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam
Description: 50mg tablets
Study: NCT04289714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel Electronic Monitoring Device
Description: Four Novel electronic Monitoring Devices were trialled
Study: NCT01215357

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ecopipam
Description: 50mg tablets
Study: NCT01149213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: tDCS will be applied at 2mA/30 minutes, every other week during the first three months than once a month during the next three months.
Study: NCT04454086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Undergo aerobic exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Counseling
Description: Receive behavioral activity counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Assessment
Description: Receive nutritional counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Undergo resistance exercises
Study: NCT00332605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone plus N-Acetyl Cysteine
Description: daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily
Study: NCT04289714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel Electronic Monitoring Device
Description: Four Novel electronic Monitoring Devices were trialled

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel Electronic Monitoring Device
Description: Four Novel electronic Monitoring Devices were trialled
Study: NCT04962438

Intervention type: DRUG
Intervention: Anti-VEGF
Description: Anti-tumor drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway
Study: NCT04412590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vermont Family Based Approach
Description: Comprehensive and individualized program to promote emotional health and wellbeing in families using evidence-based health promotion, prevention and intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Pediatric care as usual.
Study: NCT04535336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitality acupunch (VA) exercise program
Description: The VA had 3 phases and took 40 minutes to complete.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants maintained their daily activities.
Study: NCT01472562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Induction phase: 20 mg/day for days 1-21 of a 28-day cycle for 12 cycles. If no excess toxicity is observed the dose will be increased to 25 mg/day.~Maintenance phase: Lenalidomide will be given at 15 mg/day for days 1-21 of a 28-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Induction phase: Rituximab will be administered at 375 mg/m2 per dose for a total of 9 doses. The first 4 doses will be administered weekly starting on day 1 of lenalidomide (e.g. days 1, 8, 15 and 22). Subsequent rituximab doses will be administered for one dose each at weeks 12, 20, 28, 36 and 44.~Maintenance phase: Rituximab at 375 mg/m2 per dose will be administered for one dose every 8 weeks, starting at week 52.
Study: NCT02375282

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ambulation orderly
Description: The responsibility of the ambulation orderly is to walk patients after having a cardiac surgery, such as a coronary artery bypass surgery or a valve surgery. Baystate Medical Center hired an ambulation orderly May 8, 2013. The ambulation orderly is generally a high school graduate with some training in safe lifting and exercise, but extensive training is not required. In general, the goal is to have 1 ambulation orderly present 7 days a week for 8 hr per day. When available, ambulation orderlies are responsible for walking the patients who have been cleared by the clinical exercise physiologist or nurse up to 4 times per day. The walking of the patients occurs through the halls of the 6th floor of the Mass Mutual wing of Baystate Medical Center.
Study: NCT04080310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin
Description: This study is a multicenter, randomized, open-label, parallel, phase IV trial. The study is planned to include 272 patients with clinical ASCVD requiring optimal statin therapy.~After enrollment, subjects are randomized into two groups in a 1:1 manner. patients in combination therapy group(rosuvastation 10mg and ezetimibe 10mg daily) will be provided a fixed-dose single pill comibation and patients in the intensive statin group will receive rosuvastatin 20mg daily.

Intervention type: DRUG
Group type: OTHER
Intervention: Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin
Description: This study is a multicenter, randomized, open-label, parallel, phase IV trial. The study is planned to include 272 patients with clinical ASCVD requiring optimal statin therapy.~After enrollment, subjects are randomized into two groups in a 1:1 manner. patients in combination therapy group(rosuvastation 10mg and ezetimibe 10mg daily) will be provided a fixed-dose single pill comibation and patients in the intensive statin group will receive rosuvastatin 20mg daily.
Study: NCT00868699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lurasidone
Description: lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lurasidone
Description: lurasidone 20 mg/day for Days 1-7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT01834222

Intervention type: BIOLOGICAL
Intervention: Non-intervention
Description: Non-intervention
Study: NCT02665702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVB
Description: 25mg/m2 ，D1，8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDP
Description: 75mg/m2 ，D1 or 25mg/m2 D1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: 15mg/d，d1-d7 civ
Study: NCT04935723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: The study was conducted as a three-group interventional randomized controlled trial to examine the effect of Reiki touch therapy on surgical fear, pain, anxiety and vital signs in patients undergoing open abdominal surgery. Reiki was applied to the first group and sham reiki to the second group. Group 3 formed the control group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reiki
Description: The study was conducted as a three-group interventional randomized controlled trial to examine the effect of Reiki touch therapy on surgical fear, pain, anxiety and vital signs in patients undergoing open abdominal surgery. Reiki was applied to the first group and sham reiki to the second group. Group 3 formed the control group.